San Raffaele
Prostate cancer treatment cost in Italy is determined by the diagnostic baseline and chosen therapeutic modality. A PSA test typically costs $100 to $100, while a robotic da Vinci prostatectomy runs from $25,200 to $28,000. Total expenses depend on the cancer stage, hospital tier, and surgical approach. International patients can save 30-50% compared to US private healthcare. Top treatment centers are located in Milan, Rome, and Bologna.
Typical Prostate Cancer Treatment Costs in Italy
Bookimed Expert Insight: For high-precision requirements, robotic surgery at Ospedale San Carlo di Nancy is a top-rated choice. Patients seeking world-renowned experts should consider San Raffaele, where Professor Francesco Montorsi performs urological surgeries. If multidisciplinary care is needed, JCI-accredited Maria Cecilia Hospital provides specialized urological oncology. Early-stage patients benefit from standard laparoscopic options at San Donato Hospital to manage costs effectively.
| Włochy | Turcja | Austria | |
| Tomoterapia | od $32,000 | od $12,000 | od $30,000 |
| Terapia protonowa | od $70,000 | od $70,000 | od $80,000 |
| Terapia deprywacyjna androgenowa | od $3,000 | od $1,500 | od $4,500 |
| Terapia HIFU przy raku prostaty | od $12,000 | od $7,000 | od $12,000 |
| TURP (przezcewkowa resekcja prostaty) | od $3,600 | od $3,580 | od $5,500 |
Prof. Montorsi wykonał ponad 8 000 operacji urologicznych. W centrum medycznym San Raffaele specjalizuje się w małoinwazyjnych i robotycznych technikach leczenia raka prostaty.
Kierownik Oddziału Radioterapii w szpitalu San Raffaele — prof. Di Muzio specjalizuje się w metodach precyzyjnej radioterapii hipofrakcjonowanej w leczeniu raka prostaty i posiada ponad 25-letnie doświadczenie.
Dr. Alessandro Calarco is a skilled urologist with expertise in minimally invasive and endourological procedures. He performs percutaneous lithotripsy, ureterorenoscopy, tumor ablation, and advanced reconstructive surgeries. Dr. Calarco has received international recognition for his clinical work and research. He completed advanced training in Sweden and the UK.
Dr. Calarco graduated with top honors from Università Cattolica del Sacro Cuore in Rome. He completed his Urology specialization and earned a PhD in Oncological Urology at the same university. His research focuses on prostate cancer biomarkers and exosomes. He has also helped develop clinical protocols for hormone-refractory prostate cancer.
He serves as National Head of Urology for SPIGC and is a member of the European Board of Urology. Dr. Calarco holds an international patent for a device that improves percutaneous nephrolithotripsy. He has published extensively and received several awards for surgical innovation and education.